Scan Oscar Health’s latest guidance shift in the context of a broader peer set by hunting for insurers and healthcare players with similar earnings momentum in the curated 37 healthcare AI stocks.
For an investor to own Oscar Health, there needs to be confidence that the current profitability is durable and that the business can keep converting premium growth into earnings without letting medical costs run away. The raised 2026 revenue and operating earnings guidance points to management seeing enough visibility in membership and pricing to support stronger near term performance.
The key short term catalyst is continued proof that underwriting discipline holds through upcoming renewal cycles while the member base grows. The largest risk is that medical loss trends or pricing missteps erode margins, which would challenge the new guidance and reopen questions about the sustainability of Oscar Health’s earnings profile.
The HealthEx collaboration looks most relevant here because it plugs directly into Oscar Health’s thesis as a tech driven insurer. Members can choose to connect medical records from clinics, hospitals, and labs into the Oscar app from day one, which gives the insurer a more complete view of conditions, medications, and prior care pathways.
That operationally matters for both catalysts and risks. Better data may help Oscar match members to in network doctors, manage chronic conditions earlier, and reduce avoidable high cost claims, which feeds into earnings quality. At the same time, the integration increases reliance on secure data handling and consistent execution in the app, so any issues around privacy, uptime, or user experience could dent trust and reduce the practical benefit of the partnership.
J_Tyrader’s narrative reaches a fair value of US$583.34 for Oscar Health by applying a two stage DCF that assumes 25.0% annual growth for 10 years, fading to a 2.5% terminal rate and discounting those cash flows at 9.6%.
Uncover how Oscar Health's fair value indicates a 1762% potential increase from its current price that may not last much longer.
Some of the highest ranked analysts were already leaning into Oscar Health’s tech stack as a catalyst, expecting revenue of about US$30.4b and earnings near US$1.3b by 2029, compared with around US$550.7m of earnings in their starting point. Those projections did not factor in this HealthEx rollout, so you may see those stories evolve.
Explore 5 other Oscar Health fair value estimates, including one that suggests up to 1762% upside from the current price!
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
Once you have formed a view on Oscar Health, it can help to line it up against a wider opportunity set so you can decide where it fits in your portfolio.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com